L9LS MAb in Malian Infants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

June 27, 2025

Study Completion Date

June 30, 2026

Conditions
Malaria
Interventions
BIOLOGICAL

L9LS

Administered intramuscularly one time.

OTHER

Normal Saline

Administered intramuscularly one time.

Trial Locations (3)

Unknown

Faladje MRTC Clinic, Faladié

Kalifabougou MRTC Clinic, Kalifabougou

Torodo MRTC Clinic, Torodo

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

University of Washington

OTHER

collaborator

Harvard School of Public Health (HSPH)

OTHER

collaborator

Indiana University School of Medicine, Indiana University

UNKNOWN

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT06461026 - L9LS MAb in Malian Infants | Biotech Hunter | Biotech Hunter